Modality
mRNA
MOA
AHRant
Target
Tau
Pathway
Sphingolipid
NMOSDT2D
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Oct 2028
Phase 1Current
NCT08772419
193 pts·T2D
2018-02→2028-10·Not yet recruiting
193 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-052.5y awayInterim· T2D
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2028-10-05 · 2.5y away
T2D
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08772419 | Phase 1 | T2D | Not yet recr... | 193 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Terazumab | Rapport Ther | Phase 2 | BTK | |
| TER-5062 | Terns | Phase 2/3 | Tau |